Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates